MET and hepatocellular carcinoma: Also, HCC patients who are intolerant to sorafenib or have high expression of cellular mesenchymal–epithelial transition factor (c-MET) were found to benefit from Tivantinib therapy, a highly selective inhibitor of c-MET receptor tyrosine kinase [85, 86].